Worldwide connection at EuroFlow MRD Course in Prague

February 20, 2026

---

Measurable Residual Disease (MRD) is a key factor in modern hemato-oncology. By detecting tiny numbers of remaining cancer cells after treatment — often missed by standard tests — MRD helps predict relapse and guides decisions on treatment intensity.

One of the methods to assess MRD is flow cytometry. Last week, the EuroFlow consortium welcomed 40 professionals from six continents to Prague for the 2nd EuroFlow Winter Course on MRD. During this intensive three-day program, which was held at the beautiful Karolinum complex of the Charles University, experts shared insights on B- and T-lymphoblastic leukemia (B-ALL, T-ALL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL).
Participants learned the EuroFlow procedures, data analysis, and the use of Infinicyt databases, followed by hands-on training in small groups.
Beyond advancing knowledge, the course offered valuable opportunities for networking and collaboration with peers and experts from around the world.

Also interested to follow a EuroFlow course or school? The EuroFlow Training and Education committee is organizing many more educational opportunities. Please keep an eye on the EuroFlow Campus page to see what is going on.